ATE471945T1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents

Als medikament geeignete lösliche varianten des gp130-moleküls

Info

Publication number
ATE471945T1
ATE471945T1 AT06841152T AT06841152T ATE471945T1 AT E471945 T1 ATE471945 T1 AT E471945T1 AT 06841152 T AT06841152 T AT 06841152T AT 06841152 T AT06841152 T AT 06841152T AT E471945 T1 ATE471945 T1 AT E471945T1
Authority
AT
Austria
Prior art keywords
soluble
medication
molecule used
soluble variants
polypeptide
Prior art date
Application number
AT06841152T
Other languages
English (en)
Inventor
Dirk Seegert
Georg Waetzig
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE471945T1 publication Critical patent/ATE471945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
AT06841152T 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls ATE471945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028420A EP1801121A1 (de) 2005-12-23 2005-12-23 Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel
PCT/EP2006/012515 WO2007071449A1 (en) 2005-12-23 2006-12-22 Soluble gp130 molecule variants useful as a medicament

Publications (1)

Publication Number Publication Date
ATE471945T1 true ATE471945T1 (de) 2010-07-15

Family

ID=36233865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841152T ATE471945T1 (de) 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls

Country Status (9)

Country Link
US (1) US7851182B2 (de)
EP (2) EP1801121A1 (de)
JP (1) JP5390191B2 (de)
AT (1) ATE471945T1 (de)
AU (1) AU2006328909A1 (de)
CA (1) CA2633213A1 (de)
DE (1) DE602006015103D1 (de)
ES (1) ES2347694T3 (de)
WO (1) WO2007071449A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
WO2009014263A1 (ja) * 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP2050759A1 (de) * 2007-10-19 2009-04-22 CONARIS research institute AG Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität
MD3227325T2 (ro) 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
MX2017007067A (es) 2014-12-01 2018-04-30 Ferring Bv Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.
US20190002915A1 (en) * 2015-12-14 2019-01-03 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
CA2344277A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
EP1141013A2 (de) * 1999-01-07 2001-10-10 Lexigen Pharmaceuticals Corp. Expression und export von proteinen gegen fettleibigkeit als fc-fusionsproteine
ATE382636T1 (de) * 2000-04-21 2008-01-15 Conaris Res Inst Ag Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
CA2463003A1 (en) * 2001-10-19 2003-04-24 Zymogenetics, Inc. Dimerized growth factor and materials and methods for producing it
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility

Also Published As

Publication number Publication date
DE602006015103D1 (de) 2010-08-05
AU2006328909A1 (en) 2007-06-28
US7851182B2 (en) 2010-12-14
US20090227499A1 (en) 2009-09-10
ES2347694T3 (es) 2010-11-03
JP2009520480A (ja) 2009-05-28
EP1801121A1 (de) 2007-06-27
JP5390191B2 (ja) 2014-01-15
EP1994053A1 (de) 2008-11-26
EP1994053B1 (de) 2010-06-23
WO2007071449A1 (en) 2007-06-28
CA2633213A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
Schiraldi et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
Bai et al. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent
Tan et al. Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1)
Yates-Binder et al. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis
Hovanessian Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin
TW200730539A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
Al Hmada et al. Mechanisms of melanoma progression and treatment resistance: role of cancer stem-like cells
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
ATE457728T1 (de) Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
JP2012522529A5 (de)
HRP20050416A2 (en) Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
MX2024002862A (es) Enlazadores para usar en conjugados fármaco-anticuerpo.
EP1465990A4 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
ATE471945T1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
Voltà-Durán et al. Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering
Meng et al. High-yield expression, purification and characterization of tumor-targeted IFN-α2a
Gironda-Martínez et al. Identification and validation of new interleukin-2 ligands using DNA-encoded libraries
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
Ensenberger et al. Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin
Liu et al. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin
EA202193040A1 (ru) Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties